Magnesium intervention during pregnancy
| ISRCTN | ISRCTN98365455 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN98365455 |
| Protocol serial number | N/A |
| Sponsor | Sodra Alvsaborgs Hospital (Sweden) |
| Funder | South Alvsborg Research and Development Council (Forskning och Utveckling [FoU]) (Sweden) |
- Submission date
- 23/08/2010
- Registration date
- 14/09/2010
- Last edited
- 05/11/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Ragnar Rylander
Scientific
Scientific
Bjorkasvagen 21
Lerum
443 91
Sweden
| Phone | +46 (0)708 40 0101 |
|---|---|
| envhealth@biofact.se |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Double blind interventional randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Acid-base balance and blood pressure during pregnancy: a double-blinded randomized controlled trial |
| Study objectives | Intervention with magnesium citrate will prevent increase in blood pressure during last part of pregnancy. Further reading: http://www.ncbi.nlm.nih.gov/pubmed/20135136. |
| Ethics approval(s) | The Gothenburg Committee, 08/03/2009, ref: 098-09 |
| Health condition(s) or problem(s) studied | Pregnancy |
| Intervention | Magnesium citrate powder (Diasporal), 12 mmol magnesium daily, taken at week 25 of pregnancy until delivery. Control group receive no supplements. Blood pressure and proteinurea are measured routinely in all pregnancies |
| Intervention type | Other |
| Primary outcome measure(s) |
Blood pressure increase during final weeks of pregnancy |
| Key secondary outcome measure(s) |
Symptoms of pre-eclampsia during final weeks of pregnancy |
| Completion date | 01/10/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Female |
| Target sample size at registration | 60 |
| Key inclusion criteria | 1. First time pregnancies 2. Urinary calcium excretion in excess of 6 mmol around pregnancy week 20 |
| Key exclusion criteria | History of blood pressure or renal dysfunction |
| Date of first enrolment | 01/10/2010 |
| Date of final enrolment | 01/10/2012 |
Locations
Countries of recruitment
- Sweden
Study participating centre
Bjorkasvagen 21
Lerum
443 91
Sweden
443 91
Sweden
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/12/2013 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
